MaaT Pharma S.A.
MAAT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €3,216 | €2,228 | €1,430 | €972 |
| % Growth | 44.3% | 55.8% | 47.1% | – |
| Cost of Goods Sold | €1,250 | €1,444 | €339 | €166 |
| Gross Profit | €1,966 | €784 | €1,091 | €806 |
| % Margin | 61.1% | 35.2% | 76.3% | 82.9% |
| R&D Expenses | €27,477 | €20,297 | €14,476 | €9,145 |
| G&A Expenses | €2,662 | €2,351 | €1,465 | €1,167 |
| SG&A Expenses | €3,508 | €5,097 | €1,812 | €1,384 |
| Sales & Mktg Exp. | €846 | €650 | €505 | €357 |
| Other Operating Expenses | -€591 | €0 | -€1,641 | -€830 |
| Operating Expenses | €30,394 | €25,394 | €14,647 | €9,699 |
| Operating Income | -€28,428 | -€19,943 | -€13,556 | -€8,893 |
| % Margin | -884% | -895.1% | -948% | -914.9% |
| Other Income/Exp. Net | -€3,993 | €226 | -€156 | -€126 |
| Pre-Tax Income | -€32,421 | -€19,717 | -€13,713 | -€9,019 |
| Tax Expense | -€3,517 | €0 | €0 | €0 |
| Net Income | -€28,904 | -€19,717 | -€13,713 | -€9,019 |
| % Margin | -898.8% | -885% | -959% | -927.9% |
| EPS | -2.2 | -1.73 | -1.39 | -3.72 |
| % Growth | -27.2% | -24.5% | 62.6% | – |
| EPS Diluted | -2.2 | -1.73 | -1.39 | -3.72 |
| Weighted Avg Shares Out | 13,065 | 11,365 | 9,892 | 2,427 |
| Weighted Avg Shares Out Dil | 13,065 | 11,365 | 9,892 | 2,427 |
| Supplemental Information | – | – | – | – |
| Interest Income | €391 | €639 | €45 | €121 |
| Interest Expense | €868 | €413 | €201 | €121 |
| Depreciation & Amortization | €1,692 | €871 | €429 | €328 |
| EBITDA | -€26,344 | -€22,066 | -€13,099 | -€8,570 |
| % Margin | -819.2% | -990.4% | -916% | -881.7% |